Hypaque 50 en es it fr

Hypaque 50 Brand names, Hypaque 50 Analogs

Hypaque 50 Brand Names Mixture

  • No information avaliable

Hypaque 50 Chemical_Formula

C9H15N5O3

Hypaque 50 RX_link

No information avaliable

Hypaque 50 fda sheet

Hypaque 50 msds (material safety sheet)

Hypaque 50 Synthesis Reference

No information avaliable

Hypaque 50 Molecular Weight

241.247 g/mol

Hypaque 50 Melting Point

250-255 oC (hydrochloride salt)

Hypaque 50 H2O Solubility

>20 mg/mL (dichloride salt)

Hypaque 50 State

Solid

Hypaque 50 LogP

-1.783

Hypaque 50 Dosage Forms

No information avaliable

Hypaque 50 Indication

For the treatment of tetrahydrobiopterin (BH4) deficiency.

Hypaque 50 Pharmacology

Tetrahydrobiopterin (BH4) is used to convert several amino acids, including phenylalanine, to other essential molecules in the body including neurotransmitters. Tetrahydrobiopterin deficiency can be caused by mutations in GTP cyclohydrolase 1 (GCH1), 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1), 6-pyruvoyltetrahydropterin synthase (PTS), and quinoid dihydropteridine reductase (QDPR) genes. These genes make the enzymes that are critical for producing and recycling tetrahydrobiopterin. If one of the enzymes fails to function correctly because of a gene mutation, little or no tetrahydrobiopterin is produced. As a result, phenylalanine from the diet builds up in the bloodstream and other tissues and can damage nerve cells in the brain. High levels of phenylalanine can result in signs and symptoms ranging from temporary low muscle tone to mental retardation, movement disorders, difficulty swallowing, seizures, behavioral problems, progressive problems with development, and an inability to control body temperature.

Hypaque 50 Absorption

No information avaliable

Hypaque 50 side effects and Toxicity

No information avaliable

Hypaque 50 Patient Information

No information avaliable

Hypaque 50 Organisms Affected

Humans and other mammals